Infliximab therapy for ulcerative colitis: Many unanswered questions

American Journal of Gastroenterology

Volumn 96, Issue 8, 2001, Pages 2294-2296

  Present, Daniel H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

CANCER RISK; DRUG EFFECT; DRUG EFFICACY; DRUG USE; EDITORIAL; HUMAN; LYMPHOMA; PRIORITY JOURNAL; TREATMENT INDICATION; ULCERATIVE COLITIS;

EID: 0034882374     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02594-1     Document Type: Note

References (9)

1. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
2. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease
3. Infliximab for the treatment of fistulas in patients with Crohn's disease
4. Infliximab in Crohn's disease. First anniversary clinical experience
5. Clinical experience with Infliximab therapy in 100 patients with Crohn's disease
6. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic. The first 100 patients
7. Infliximab for refractory ulcerative colitis
8. Cyclosporin in severe ulcerative colitis refractory to steroid therapy
9. The relationship between Infliximab treatment and lymphoma in Crohn's disease